About Ascenta Capital
Ascenta Capital is a venture capital firm founded in 2023. It is primarily based out of New York City, United States. As of Jun 2026, Ascenta Capital is an active investor, having invested in 10 companies, with 4 new investments in the last 12 months. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Triveni Bio Overall, Ascenta Capital portfolio has seen 1 IPO and 1 acquisition, namely Odyssey and Tubulis Technologies. A lot of funds co-invest with Ascenta Capital, with names like Janus Henderson Investors sharing a substantial percentage of its portfolio. Ascenta Capital has team of 4 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series C, Series B & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Ascenta Capital's List of Top Investments
Ascenta Capital has a portfolio of 10 companies. Their most notable investments are in Odyssey and Cardurion.Their portfolio spans across United States, China and Germany. They have invested in Life Sciences, High Tech, Enterprise Applications and 1 other sectors, across stages such as Series C, Series B and 1 more. Here is the list of top investments by Ascenta Capital:
1. Odyssey
Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.
Key facts about Odyssey
- Founded Year: 2018
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $717M
- Employee Count: 123 as on Jul 31, 2026
- Investors: Colt Ventures, T. Rowe Price and 29 Others
- Latest Funding Round: Series D, Jun 16, 2025, $*****
- Highlight: Public
Developer of antibody-drug conjugates for the treatment of cancer. The company has proprietary technology platforms which include the Tub-tag conjugation platform, P5 conjugation platform, and Topoisomerase-I inhibitor platform to develop antibody-drug conjugates for solid and hematological tumors. It offers TUB-040 for ovarian and non-small cell lung cancer. TUB-030, TUB-050, and TUB-060 for solid tumors.
Key facts about Tubulis Technologies
- Founded Year: 2015
- Location: Munich (Germany)
- Stage: Acquired
- Total Funding till date: $615M
- Employee Count: 117 as on Jul 31, 2026
- Investors: Fidelity Investments, Frazier Life Sciences and 27 Others
- Latest Funding Round: Series C, Oct 15, 2025, $*****
- Highlight: Acquired
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.
Key facts about Iambic Therapeutics
- Founded Year: 2019
- Location: San Diego (United States)
- Stage: Series C
- Total Funding till date: $334M
- Employee Count: 173 as on Jul 31, 2026
- Investors: Sequoia Capital, Pegasus Tech Ventures and 26 Others
- Latest Funding Round: Series C, Apr 01, 2026, $*****
- Highlight: Editors' Pick
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts. The company has genetic therapeutics that precisely target RNA transcripts to enable the production of desired proteins. It helps in the nucleotide sequence specified in the genomic template that is modified to produce a different nucleotide sequence in the transcript.
Key facts about ADARx Pharmaceuticals
- Founded Year: 2019
- Location: San Diego (United States)
- Stage: Series C
- Total Funding till date: $353M
- Employee Count: 98 as on Jul 31, 2026
- Investors: T. Rowe Price, Bain Capital Life Sciences and 17 Others
- Latest Funding Round: Series C, Aug 02, 2023, $*****
- Highlight: Editors' Pick
5. Angitia
Developer of drugs for muscle, bone, and joint diseases. The company's products include AGAO1 for bone fusion, AGA02 for rare diseases, AGA03 for regeneration, AGA04 for osteoporosis, AGA05 for healing, and others. Also, developed many drugs for multiple disease treatments such as nonunion of fractures, osteoarthritis, rare diseases of skeletal muscle, and mineral metabolism diseases caused by diseases or disorders of endocrine organs.
Key facts about Angitia
- Founded Year: 2018
- Location: Woodland Hills (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $406M
- Employee Count: 63 as on Jul 31, 2026
- Investors: Bain Capital Life Sciences, BVF Partners and 28 Others
- Latest Funding Round: Series D, Feb 05, 2026, $*****
- Highlight: Editors' Pick
Ascenta Capital's Year-on-Year Investment Trends
Ascenta Capital has invested in 10 companies over the last 3 years, with an average of 3 new investments annually in the last 3 years. In 2025, it made 3 investments, while as of Jun 2026, it has made 2 investments in this year. Its most recent first time investment was in Triveni Bio and most recent follow-on round was in Iambic Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 0 | 2 |
2025 | 2 | 1 | 3 |
2024 | 3 | 0 | 3 |
2023 | 3 | 1 | 4 |
Ascenta Capital's Investments by Stage
Ascenta Capital has made 5 investments in Series C stage with an average round size of $161M, 4 investments in Series B stage with an average round size of $138M and 1 investment in Series D stage with an average round size of $130M.Stage of entry | No. of Investments |
|---|---|
Series C | 5 |
Series B | 4 |
Series D | 1 |
Note: We have considered here, only first round of investments
Ascenta Capital's Investments by Sector
Ascenta Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Artificial Intelligence - Industry Applications, Enterprise Applications and HealthTech. Notably, it has invested in 10 Enterprise (B2B) companies, 10 Tech companies, 1 AI-Native company and 1 company focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 10 |
High Tech | 2 |
Artificial Intelligence - Industry Applications | 1 |
Enterprise Applications | 1 |
HealthTech | 1 |
Note: We have considered here, only first round of investments
Ascenta Capital's Investments by Geography
Ascenta Capital has made most investments in United States (9), followed by China where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 9 |
China | 1 |
Germany | 1 |
Note: We have considered here, only first round of investments
Ascenta Capital's recent investments
Ascenta Capital has made 2 investments in 2026 so far - Triveni Bio and Angitia.Here are the most recent investments by Ascenta Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 17, 2026 | United States | Series C | 1854 | ||
Feb 05, 2026 | United States | Series D | 7421 | [+16] | |
Nov 26, 2025 | United States | Series B | 4799 | ||
Nov 06, 2025 | United States | Series C | 2414 | [+15] | |
Oct 15, 2025 | Germany | Series C | 4962 | [+14] |
IPOs and Publicly Listed companies in Ascenta Capital's Portfolio
1 of Ascenta Capital's portfolio company became public - Odyssey. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2026 at marketcap of $849MHere are Ascenta Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 08, 2026 | Oct 25, 2023 | Series C | 8994 |
Acquired companies in Ascenta Capital's Portfolio
1 company from Ascenta Capital's portfolio has been acquired. The most recent acquisition was Tubulis Technologies in Apr 2026 by Gilead for $*****.Here are Ascenta Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 07, 2026 | Oct 15, 2025 | Series C | 9961 |
Team profile of Ascenta Capital
Ascenta Capital has a team of 4 members including 3 Partners located in United States. Ascenta Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Ascenta Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Boston | - | - | |
Partner | New York City | - | ||
Partner | Newton Highlands | - | - |
Co-investors of Ascenta Capital
Over the past 3 years, 150 investors have co-invested in Ascenta Capital's portfolio companies. This includes funds and angels.
- Invested before Ascenta Capital: Orbimed, Alexandria and 71 others have invested in rounds before Ascenta Capital. There are 5 companies where Orbimed has invested before Ascenta Capital and 2 companies where Alexandria has invested before Ascenta Capital.
- Top Co-investors of Ascenta Capital: 45 investors entered a company along with Ascenta Capital. These include investors like Janus Henderson Investors (4 companies).
- Invested after Ascenta Capital: A total of 32 investors have invested in Ascenta Capital's portfolio after their investments. Top Investors include Jeito (1 company), Affinity Asset Advisors (1 company) and Dimension (1 company).
Recent News related to Ascenta Capital
•
Leads Biolabs Partner Oblenio Bio Secures $62 Million Series B Financing for Autoimmune Disease Drug LBL-051GlobeNewswire•Jun 25, 2026•Nanjing Wei Li Zhi Bo Biotechnology, Pfizer, Aditum Bio, Deep Track Capital and 4 others
•
•
•
•
•
Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)Business Wire•Oct 30, 2025•Ascenta Capital, Frazier Life Sciences, Fidelity Investments, Deep Track Capital and 13 others
•
Tubulis Secures €308 Million to Advance Antibody-Drug Conjugate InnovationEU-Startups•Oct 15, 2025•Tubulis Technologies, Venrock, Ascenta Capital, Frazier Life Sciences and 12 others
•
•
Radiopharma biotech Alpha-9 Oncology closes $175M Series C fundraiseEndPoints News•Oct 23, 2024•Alpha-9 Oncology, Janus Henderson Investors, Delos Capital, Digitalis Ventures and 12 others
•
OrsoBio gains funds to develop obesity portfolioPharmaceutical Technology•Sep 09, 2024•OrsoBio, Ascenta Capital, Woodline Partners, Samsara BioCapital and 2 others
